Exosome profiling for diagnosis and monitoring of vasculitis and vasculopathies including Kawasaki disease
AssigneeSeattle Children's Research Hospital
InventorMichael Portman
Life of this patent
Estimating the term…
Abstract
Some embodiments of the methods and compositions provided herein relate to the detection of biomarkers for Kawasaki disease (KD), the diagnosis of KD in a subject, and/or the amelioration or treatment of KD in a subject. In some embodiments, a biomarker can include a long intergenic non-coding RNA (lincRNA). In some embodiments, the biomarker can be present in an exosome-enriched serum sample from a subject.
Claims18
A method for treating, inhibiting or ameliorating Kawasaki disease (KD) in a human subject, comprising:
- (i) detecting a KD biomarker in a biological sample from a human subject comprising:
- (a) providing a population of nucleic acids prepared from the biological sample, wherein the biological sample is enriched for CD31+ exosomes,
- (b) hybridizing a probe with the population of nucleic acids, wherein the probe is capable of detecting linc-ZNF337-1, and
- (c) detecting the presence of linc-ZNF337-1 in the biological sample,
- (d) identifying the subject as having KD when linc-ZNF337-1 is present;
- and
- (ii) administering a therapy for the KD to the subject having KD, wherein the therapy comprises an effective amount of a composition selected from the group consisting of an intravenous immunoglobulin, aspirin, and a corticosteroid.
A method for treating, inhibiting or ameliorating Kawasaki disease (KD) in a human subject, comprising:
- (i) identifying a human subject having KD, comprising:
- (a) obtaining a library of nucleic acids prepared from RNA polynucleotides of a biological sample from the subject, wherein the biological sample is enriched for CD31+ exosomes,
- (b) sequencing the library of nucleic acids,
- (c) determining the presence of a nucleotide sequence of a KD biomarker in the library of nucleic acids, wherein the KD biomarker comprises linc-ZNF337-1,
- (d) identifying the human subject as having KD when linc-ZNF337-1 is present in the biological sample;
- and
- (ii) administering a therapy for the KD to the subject having KD, wherein the therapy comprises an effective amount of a composition selected from the group consisting of an intravenous immunoglobulin, aspirin, and a corticosteroid.
Dependencies are inferred from the claim text.